<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758524</url>
  </required_header>
  <id_info>
    <org_study_id>CLCI699A2201</org_study_id>
    <nct_id>NCT00758524</nct_id>
  </id_info>
  <brief_title>A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a proof-of-efficacy, dose finding study of LCI699 in patients with
      mild-to-moderate uncomplicated essential hypertension in order to assess the BP lowering
      effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean sitting diastolic blood pressure reduction</measure>
    <time_frame>After 8 weeks of double-blind treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of mean sitting systolic blood pressure</measure>
    <time_frame>After 8 weeks of double-blind treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">526</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LCI699 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LCI699 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LCI699 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LCI699 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCI699</intervention_name>
    <arm_group_label>LCI699 1</arm_group_label>
    <arm_group_label>LCI699 2</arm_group_label>
    <arm_group_label>LCI699 3</arm_group_label>
    <arm_group_label>LCI699 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-fertile females

          -  18-75 years inclusive

          -  Patients with mild-to-moderate uncomplicated essential hypertension

        Exclusion Criteria:

          -  All women of child bearing potential.

          -  Female patients on hormone replacement therapy.

          -  Severe hypertension

          -  History or evidence of a secondary form of hypertension

          -  Known moderate or malignant retinopathy

          -  History of angina pectoris, myocardial infarction, coronary bypass surgery,ischemic
             heart disease, surgical or percutaneous arterial intervention of any kind (coronary,
             carotid or peripheral vessels), stroke, transient ischemic attack (TIA), carotid
             artery stenosis, aortic aneurysm or peripheral arterial disease.

          -  Type 1 or type 2 diabetes mellitus.

          -  Clinically significant valvular heart disease.

          -  Congestive heart failure (NYHA class II-IV).

          -  Cardiac electrical abnormalities indicating significant risk of safety for patients
             participating in the study

          -  History of malignancy of any organ system, treated or untreated, within the past 5
             years.

          -  Liver disease such as cirrhosis or chronic active hepatitis.

          -  Any surgical or medical conditions that may significantly alter the absorption,
             distribution, metabolism or excretion of any drug substance

          -  Any surgical or medical conditions, not identified in the protocol that in the opinion
             of the investigator or the monitor, place the patient at higher risk from his/her
             participation in the study, or is likely to prevent the patient from complying with
             the requirements of the study or completing the trial period.

          -  Patients unwilling or not able to discontinue safely the use of current
             antihypertensive medications during the study period

          -  Any contraindication or history of hypersensitivity to any of the study drugs or to
             drugs with similar chemical structures.

          -  Chronic oral or parenteral corticosteroid treatment

          -  Treatment with potassium supplement or potassium sparing diuretics

          -  Treatment with potent CYP3A4 inhibitors during the study period

          -  Use of other investigational drugs at Visit 1, or within 30 days or 5 half-lives of
             Visit 1, whichever is longer, unless local health authority guidelines mandate a
             longer period.

          -  Serum potassium &gt; 5.2 mEq/L or &lt; 3.5 mEq/L at Visit 1.

          -  Serum sodium &lt; 132 mEq/L at Visit 1.

          -  ALT or AST &gt; 2 times the upper limit of the normal range (ULN) at Visit 1.

          -  Bilirubin (total) &gt; 1.5 x ULN at Visit 1.

          -  MDRD eGFR &lt; 60 ml/min/1.73 m2 at Visit 1.

          -  Other clinically significant laboratory abnormalities, confirmed by repeat
             measurements, at Visit 1.

          -  History of active substance abuse (including alcohol)

          -  Patients with night-shift employment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <disposition_first_submitted>May 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 6, 2012</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>phase 2 study</keyword>
  <keyword>antihypertensive agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

